Compare Adaptive Biotechnologies Corp (ADPT) vs TeraWulf Inc (WULF) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

WULF trades at $22.21, up 4.86% with strong analyst support despite bearish technical signals. The company recently secured a transformative $19 billion AI infrastructure deal with Anthropic, shifting focus from Bitcoin mining to long-term contracted revenue. However, fundamentals show significant challenges with negative profit margins (-611.46%) and high valuation ratios (P/S 53.86, P/B 84.25) amid consecutive earnings misses.

The outlook balances substantial AI opportunity against current financial weakness. The 20-year Anthropic contract provides revenue visibility, but execution risks and negative cash flow from operations (-$123M) require careful monitoring. With 100% analyst buy ratings and $32.40 consensus target offering 46% upside, the stock presents high-risk, high-reward potential for investors believing in the AI infrastructure pivot.